A highly selective inhibitor of Bcr-Abl, the definitive cause of Ph+ CML, and its mutations.

1. Gallipoli P  et al. JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of chronic phase CML CD34+ cells in vitro and in vivo. Blood : (2014).

2. Zhang H  et al. Inhibition of MDM2 by nilotinib contributes to cytotoxicity in both Philadelphia-positive and negative acute lymphoblastic leukemia. PLoS One 9:e100960 (2014).